Pinealon vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Pinealon
Pinealon is a short synthetic peptide developed from research on the pineal gland. It has shown neuroprotective and cognitive-enhancing properties in animal studies.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | Pinealon | Liraglutide |
|---|---|---|
| Mechanism | Penetrates cell membranes and interacts with DNA to regulate gene expression related to neuronal survival and function. May support pineal gland function and melatonin production. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Typical dosing: 10-20mg daily, taken in divided doses. Often used in cycles of 10-20 days. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Can be taken orally (capsules) or sublingually. Best absorbed on an empty stomach. Often combined with other neuroprotective peptides. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated. Limited reported side effects. May affect sleep patterns initially. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |